Key result
Pre-existing hypertension is linked to ~10-fold higher odds of peripartum cardiomyopathy.
Why the study?
Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition often diagnosed late in advanced heart failure, prompting this comprehensive examination of its demographics, risk factors, clinical characteristics, treatment patterns, and maternal-neonatal outcomes.
Meta-Analysis (n=66,908)
This large meta-analysis of 66,908 patients with peripartum cardiomyopathy demonstrates that while 55% achieve LVEF recovery, 62% present in advanced heart failure (NYHA III/IV) and maternal (6%) and neonatal (4%) mortality remain high, underscoring the critical need for early detection and standardized guideline-directed medical therapy.
Answers are grounded in this paper and cite their sources.
Supports targeted screening in hypertensive pregnancies; extends evidence on recovery rates and mortality in peripartum cardiomyopathy.
Background Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition and often diagnosed late, with many patients presenting in advanced heart failure. This study aimed to examine the demographics, risk factors, comorbidities, clinical characteristics, treatment patterns, and maternal and neonatal outcomes Methods and Results This meta-analysis followed PRISMA guidelines. A total of 4,341 records up to May 2025, were identified and 122 eligible studies reporting PPCM clinical characteristics, treatments, and outcomes were included. Heterogeneity was explored through meta-regression analyses assessing demographic, clinical, and study-level variables. An aggregate of 66,908 PPCM patients were reported across the included studies, with a pooled mean age of 30.1 years. Black or African women accounted for a disproportionately large proportion of the reported population compared with other racial groups. Approximately 62% of women presented with advanced heart failure (NYHA class III/IV). Pre-existing diabetes mellitus (OR 5.09) and hypertensive disorders, including pre-existing hypertension (OR 10.07), gestational hypertension (OR 7.75), and pre-eclampsia (OR 9.27), were associated with higher odds of PPCM. The pooled mean LVEF at diagnosis was 29.98%, which subsequently improved to 46.47% at 6 months and 49.12% at 12 months. Despite over half of PPCM patients achieving LVEF recovery (55%), maternal mortality remained high at 6% and neonatal mortality at 4%. Pharmacological treatments for PPCM varied widely, with high heterogeneity suggesting substantial differences in prescribing practices across studies. Conclusion The high prevalence of NYHA class III/IV symptoms at diagnosis underscores the importance of early detection and monitoring, while the variation in reported use of guideline-directed medical therapy (GDMT) across studies highlights potential opportunities to optimize treatment in patients with PPCM. The observed improvement in LVEF during follow-up indicates that cardiac recovery is possible in patients with PPCM. However, these findings should be interpreted cautiously given the observational nature and substantial heterogeneity of the included studies.
No takes yet. Share an insight, caveat, or question.
Zenjaya et al. (2026) conducted a meta-analysis in Peripartum cardiomyopathy (PPCM) (n=66,908). Hypertensive disorders and pre-existing diabetes mellitus vs. Absence of risk factors was evaluated on LVEF recovery, maternal mortality, and neonatal mortality. Peripartum cardiomyopathy was strongly associated with pre-existing hypertension and pre-eclampsia, with 55% achieving LVEF recovery and 6% maternal mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: